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Abstract
Background: With the global expansion of clinical trials and the expectations of the rise of the emerging economies known
as BRICs (Brazil, Russia, India and China), the understanding of factors that affect the willingness to participate in clinical
trials of patients from those countries assumes a central role in the future of health research.
Methods: We conducted a systematic review and meta-analysis (SRMA) of willingness to participate in clinical trials among
Brazilian patients and then we compared it with Indian patients (with results of another SRMA previously conducted by our
group) through a system dynamics model.
Results: Five studies were included in the SRMA of Brazilian patients. Our main findings are 1) the major motivation for
Brazilian patients to participate in clinical trials is altruism, 2) monetary reimbursement is the least important factor
motivating Brazilian patients, 3) the major barrier for Brazilian patients to not participate in clinical trials is the fear of side
effects, and 4) Brazilian patients are more likely willing to participate in clinical trials than Indians.
Conclusion: Our study provides important insights for investigators and sponsors for planning trials in Brazil (and India) in
the future. Ignoring these results may lead to unnecessary fund/time spending. More studies are needed to validate our
results and for better understanding of this poorly studied theme.
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Introduction
With the current expansion of clinical trials around the globe,
the importance of better understanding patients motivations
across different cultures and countries is exponentially in-
creased. Assuming that ‘‘everyone should think like me’’ is no
longer an assumption that researchers from developed countries
can make, the cross-cultural motives being diverse and essential
not only for adequate recruitment but also to adjust to local
beliefs and moral values. Although there is a substantial amount
of literature on factors contributing to participation in trials in
America [1–4], little is known about this information in
developing countries.
The desire to help others is a frequent reason for participation
in studies conducted in developed countries. ‘‘Altruism’’ and
‘‘opportunity to help others’’ are cited as reasons in several studies.
Personal reasons such as health benefits, are less common [1–3].
An important factor that hinders the participation in studies is the
memory of traumatic experience, such as Tuskegee Study. The
minorities in developed countries are particularly affected by this
factor[5]. Often these groups also report the fear of their being
used as guinea pigs by the dominant class[1].
The few studies conducted in developing countries show similar
reasons, but those related to personal benefits are more common
[6–10]. A recent meta-analysis involving studies on Indian patients
showed that almost half of the patients involved in the study
wanted to participate in clinical studies for reasons such as free
treatment and improvement of their symptoms.[11]
The objective of this study is therefore to conduct a systematic
review and meta analysis of the literature regarding willingness to
participate in clinical trials among individuals in Brazil, and then
compare these findings through a dynamic model of a similar
study previously conducted by our group regarding willingness to
participate in clinical trials among individuals in India. [11]
Results
Systematic Review
The initial review of the literature resulted in 28119 articles, and
we selected 357 as relevant and excluded 27762 after reading their
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excluded 287 of them and selected 70 as relevant. After retrieving
the full text of these 70 articles, we excluded 63 of them because
one of the following reasons: 1) they did not have Brazilian
patients, or 2) the ethnicity of the participants were not mentioned,
or 3) they did not fit our inclusion criteria, or 4) lack of availability
of full text. From the remaining seven studies, we excluded more
two: one by being a report from World Health Organization with
insufficient data to be analyzed, and other due to absence of
needed data at the article and unresponsiveness of the author. This
flow chart is summarized in Figure 1. The final list of five studies
matching our inclusion and exclusion criteria is described in Table
S1. Three of the seven contacted authors replied to our request
with no new articles. No discrepancies were noted by the blinded
search and the articles found by the blinded reviewer were the
same of the ones found by the other reviewers. Observer
agreement among the two reviewers (GZ and HM) in relation to
the literature search results of title, abstract as well as full-text
eligibility were 66.7%, 28.6%, 50% respectively. The literature
search results of title and full text show moderate agreement and
the abstract show poor agreement.
Out of the five studies included in our analysis, three were
conducted in Rio de Janeiro - RJ [8–10], one in Belo Horizonte –
MG [7] and one in Salvador – BA[6]. Three of the five studies are
focused in patient participation in HIV vaccine trials (two in Rio
de Janeiro – RJ[9,10] and one in Belo Horizonte - MG [7]. The
study from Salvador - BA were focused in young women
participation in human papillomavirus vaccination trials. The
remaining study from Rio de Janeiro - RJ [8] were focused in
patient participation in general. The age of patients included range
from 16 to 50, but one study [8] did not reported the age group.
The total number of participants included in our analysis were
2920 (2024 males and 896 females) and more details can be
visualized in Table S1.
The results from our systematic review and meta-analysis were
subdivided into two groups: Factors favoring participation in
clinical trials (Table S2) and factors serving as barrier to
participation in clinical trials (Table S3). For the factors favoring
participation, we found four main themes (personal health
benefits, altruism, convenience and monetary reimbursement)
which can be seen with their respective percentages in Table S2.
For the factors serving as barrier, we also found four themes (fear
of adverse events, inconvenience, mistrust and lack of knowledge)
and more details can be seen at table S3.
Factors favoring participation in clinical trials
Altruism 55%. Altruism means ‘‘unselfish regard for or
devotion to the welfare of others’’[12]. In our study, altruism is
figuring as the main theme influencing Brazilian patients to
participate in clinical trials. Altruism appears as a decisive factor in
four out of the five articles analyzed. The reasons cited into the
articles related to altruism included the possibility both to benefit
others and the opportunity to help science.
Personal Health Benefits 30%. The personal benefits to
health were a common factors to all articles, is the second most
important factor favoring participation in clinical trials. In this
case, several reasons were interpreted as benefits to their health.
Some patients were interested in the possibility of consultations
with specialists, a more detailed consultation with the same doctor
or even the ability to consult, because there is no health service in
her city. Other interest was related to the possibility of know more
about their disease. The possibility of free benefits like HIV-test,
snacks or bus ticket were also cited.
Convenience 11%. Reasons related to convenience were
cited only in two articles. The possibility of not having to wait long
for consultation, access to drugs and tests for free were the reasons
reported in the articles related to convenience.
Monetary Reimbursement 6%. The monetary benefit was
quoted only in one article, and is the least important factor
favoring the willingness to participate in clinical trials among
Brazilian patients. Surprisingly, it was one of the least cited factors,
even in a study that involved only patients with low income and
analyzing citizens of a developing country.
It should be noted that the sum of the percentage values of
factors favoring participation in clinical trial does not equate to
100% as the patients were not limited to report one theme.
Factors serving as barrier to participation in clinical trials
Fear of Adverse Events 12%. The fear of side effects was
quoted in three of the five included studies and is the main factor
serving as barrier to participation in clinical trials according to
Brazilian patients. Besides the fear of the vaccine itself, some
patients cited fears that the vaccine could infect them with HIV or
induce that serological tests become positive.
Inconvenience 2%. Situations considered inconvenient were
the less common reasons for not participating in the studies.
Reasons like: ‘‘clinic is too far from home’’ and ‘‘need to get injections’’
were cited in one study and was related to inconvenience.
Mistrust 6%. The mistrust factor was present in three
studies. In one of them about one third of patients interviewed
said they were insecure and needed more information on the
subject before deciding. The fear of being used as guinea pigs
appeared in 2 other articles. Other reasons included: believe the
vaccine will fail, do not trust in government, in drug companies, in
the United States or in research scientists.
Lack of knowledge 4%. Lack of knowledge was a reason for
not participating in clinical trials quoted only in one of the articles.
In that study, the refuse was based on the fact of not having
sufficient information about the vaccine. It should be noted that,
the sum of the percentage values of factors serving as barriers to
Figure 1. Flowchart with inclusion and exclusion of articles.
doi:10.1371/journal.pone.0014368.g001
Clinical Trial Participation
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e14368participation in clinical trial does not equate to 100% as the
patients were not limited to report one theme
Policy model
The baseline model was then simulated with two different types
of parameters: one for Brazilian patients and the other for Indian
patients. Those parameters were the values for each element that
affect ‘Motivations to participate’ and ‘Barriers to participate’, and
were obtained from our meta-analysis and from the meta-analysis
for Indian patients conducted by our group[11] Those values were
summarized in tables S4 and S5.
After running the simulation for both scenarios (Brazilian
patients versus Indian patients), we graphically displayed the
number of clinical trials performed under the two different
conditions (Figure 2). To do justice that this model is not explicitly
predicting the amount of trials but rather representing the
behavior, we don’t provide numerical results.
Discussion
To our knowledge, this is the first study reporting results from a
systematic review and meta-analysis of factors that affects the
willingness to participate (WTP) in clinical trials for Brazilian
patients. We also believe that it is the first study reporting a system
dynamics model to compare WTP in clinical trials among
Brazilians and Indians. With the expectations of the rise of the
emerging economies known as BRIC (Brazil, Russia, India and
China)[13], allied with the knowledge of under-representation of
some ethnic and minority groups in clinical trials[14–16], this
study assumes a central role in the future of health research. Our
main results are 1) the major motivation for Brazilian patients to
participate in clinical trials is altruism, 2) monetary reimbursement
is the least important factor motivating Brazilian patients, 3) the
major barrier for Brazilian patients not to participate in clinical
trials is the fear of side effects, and 4) Brazilian patients are more
likely to be willing to participate in clinical trials than Indians.
Altruism is present as a motivational factor for participation in
clinical trials in many studies conducted in developed countries
[1,2,17,18]. The Brazilian patients involved in this study also cited
this as an important motivational factor. The ideas involved in this
factor, such as the possibility of helping the community and benefit
others in the future, were similar to those found in previous
studies[19,4,20]. Many of the Brazilian patients were in situations
related to HIV and even previous studies related to other diseases
have shown the positive influence of altruism.[2,3,4] As the desire
to ‘‘help others’’ is a common reason to participate in medical
research, recruitment strategies for clinical trials highlighting this
aspect should yield good results.
The influence of monetary incentives to participate in clinical
trials have been reported by previous studies. [21–24] A majority
of Brazilian patients included in this study have some unique
characteristics: homosexual men, intention to participate in HIV-
vaccine trials and citizens of a developing country. All these
characteristics were previously reported as factors related to the
influence of monetary incentives in the enrollment to participate in
clinical trials.[25–29], but surprisingly in our results that factor is
the least important. On the other hand, too much monetary
compensation was related to increase concerns with respect to the
safety of the research. [30] In patients with other predominant
characteristics in contrast to gay men from emerging countries, the
Figure 2. System Dynamics model.
doi:10.1371/journal.pone.0014368.g002
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in some groups [31] and having minimal influence to others.[32]
Anyway, the monetary reimbursement strategy seems to be
effective to increase the WTP some populations but not in the
studied Brazilian patients. Some ethical concerns have to be
analyzed when considering to adopt that strategy in order to
increase the WTP in clinical trials.[33]
The fear of side effects was broadly reported as a key factor
limiting the adherence to medical treatments [34–37] and the
willingness to accept vaccines. [37,38] Regarding the willingness to
participate in trials, it was also reported as an important serving as
a barrier to the willingness [39,40], and it appears as the main
barrier in some studies [41] like we are seeing in our results. For
Brazilian patients this fear is the main factor serving as a barrier to
participate in clinical trials, and is the second more important for
Indians’, reinforcing what is seen in literature.
When comparing the WTP of Brazilians’ with the Indians’ [11]
through a system dynamics model, we can see that the Brazilian
patients are more willing than Indians’ to participate in clinical
trials. It can be explained by the lower quantity of factors serving
as barrier for Brazilians’ compared to Indians’. In the hypothetical
scenario within the SD model, we compared the relative quantity
of clinical trials that would be generated over time with the same
amount of resources. The model then is showing us that the
number of clinical trials generated within Brazilian patients would
be greater than the generated with Indian patients.
Another interesting point is that 48% of the Indian patients
reported the personal health benefits as the major factor
influencing the WTP while Brazilian patients reported only
29%. A plausible explanation for that fact may rely on the
healthcare system of both countries. In Brazil, there is a publicly-
funded universal healthcare system (Sistema U ´nico de Sau ´de -
SUS, portuguese for Unified Health System). [42] In this case, any
Brazilian patient already have full healthcare support for free,
making personal health benefits not much attractive to them as a
factor influencing WTP in clinical trials. The same doesn’t occur
in India, where the healthcare system is different than what is
found in Brazil, making personal health benefits more attractive
for Indian patients.
We found moderate and poor agreement among the two
reviewers in context to their search results in the same set of
databases using the same set of keywords. Since analysis of
database search results is a qualitative process the results might
differ. Additionally we noted that the results from the blinded
reviewer was similar to the other two reviewers thus validating
their analysis.
Despite our innovative results, this study has limitations. First,
three of the five studies have evaluated the willingness of
homosexual men to participate in HIV-vaccine trials. The
limitations of it is the risk that these results don’t represent the
whole Brazilian population. In order to validate the meta-analysis
results, our plan is to continue this research project with a multi-
center survey including 200 randomly selected outpatients.
Second, a system dynamics model is an experimental method,
and its results cannot consider random and/or unexpected events.
Another limitation related to the SD model is about the fact that
the data included in the SD model were not reported in all the 5
trials as reported in table S1. Consequently, the model outputs just
represents the behavior of a system created with the data given by
us. In this case, we based our inputs totally from the literature
based on the two systematic reviews involving the Brazilian and
Indian patients. Thirdly, we could not adjust for the differences
existing between the articles included in our study due to
limitations posed by meta analysis study design. These differences
include differences in population, sample size, study objectives,
outcomes of interest and data capture.
Our conclusion is that investigators and sponsors must consider
our results when planning clinical trials to be performed in Brazil
(and India). Based in our results, the best way to incentive
Brazilian patients to participate in clinical trials is by making them
understand the altruistic side of the trial rather than trying to give
monetary incentives. Another essential point is to explain to the
patients about possible side effects. Ignore these results may lead to
unnecessary fund/time spending. More studies are needed to
validate our results and for better understanding of this poorly
studied theme.
Methods
Systematic Review and Meta-analysis
The objective of the systematic reviewing is to address the
research question ‘‘which factors influence Brazilian patients to
participate in clinical trials?’’.
Search Strategy. A systematic search was conducted by two
reviewers (GRZ, HSM) independently on the following online
databases: Pubmed (1985 to 2008), Cochrane (1983 to 2009),
CINAHL, the Cumulative Index to Nursing and Allied Health
Literature (1985 to 2008), LILACS, Latin American and
Caribbean Health Sciences (1982 to 2009) and ‘SciELO Brazil’,
Scientific Electronic Library Online (1982 to 2009). LILACS is a
biomedical database with articles from Latin America and
‘SciELO Brazil’ is a scientific database with articles from Brazil.
We used a search strategy combining the following keywords
(Appendix) relevant to our research question. The search was
restricted to studies published in English or Portuguese languages,
conducted in adult human subjects. The reviewers (GRZ, HSM)
working with the Latin American databases were fluent in
Portuguese and Spanish.
Article reference lists and articles listed under the ‘‘related
articles’’ link in PubMed were also examined for additional
articles. Finally, we subscribed to RSS (real simple syndication)
feeds corresponding to each of the search strategies that we had
devised and implemented in online databases to track new studies
published after we completed the literature review.
Selection. We defined selection criteria to filter and shortlist
study articles that would qualify for the meta synthesis. Both
reviewers (GRZ and HSM) independently evaluated the study
articles that were identified based on our search strategy. When
there was disagreement about article inclusion, it was resolved by
consensus. For inclusion in the SRMA, a study had to meet the
following criteria: 1. Involving subjects confined to Brazil (subjects
residing in Brazil or of Brazilian origin); 2. Using experimental
(trials) or qualitative methods (interviews, focus groups,
ethnographic studies, or surveys) to collect data; 3. Studies
whose outcome measures included factors affecting participation
of Brazilian subjects in clinical trials, and 4. Availability of full text
articles. We excluded studies that retrospectively analyzed clinical
trial data, studies that evaluated other Latin American
populations, unpublished articles, dissertations, and abstracts
without full text. We calculated observer agreement for the
literature search carried out by the two reviewers (GRZ, HSM).
Hand search. We classified the initial list of articles according
to the journal in which they were published, so that we could then
identify journals that had published most of the articles in our list.
Since three out of five included studies were related to HIV/
AIDS, and two of them were published in ‘JAIDS Journal of
Acquired Immune Deficiency Syndromes’, we considered JAIDS
as a key journal and performed a manual hand search through
Clinical Trial Participation
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Sep 2009.
Communication with authors. To confirm that we had
identified and retrieved all relevant studies, we communicated
through email with the corresponding authors of shortlisted
articles to inquire about the existence of any other published
studies related to our research question.
Validity assessment. To evaluate the reproducibility of our
search, an independent blinded search was performed by one of us
(AP) who focused only on the inclusion and exclusion criteria.
Data abstraction and Study characteristics. All three
reviewers (GRZ, HSM and AP) independently collected
qualitative and descriptive data from the included studies into a
spreadsheet. All data were split into specific headings including:
aim, study design, study period, eligibility criteria, geographic
location, population characteristics, source of participants, number
of participants, data analysis, outcome measures.
Percentage retrieval. We extracted data related to the
number of participants who contributed to each factor serving as
barrier or motivation to participate in clinical trials and the total
number of participants in each study. For the studies reporting the
number of responses as percentage values, we converted that value
into number through simple mathematics (percent value/100
*total number of participants). The total number of participants
contributing to each factor were then summed and percentages
were calculated for each factor based on total number of
respondents. The final results were then summarized in two
tables: factors favoring participation (Table S2) and factors serving
as barrier to participation (Table S3). Two more tables were
created to compare factors from Brazilians with Indians (Tables S4
and S5), based on results obtained from our study for Brazilian
patients and from the study for Indian patients [11].
Modeling
In order to summarize and organize the study findings and
compare results from Brazilians with Indians, we used a System
Dynamics (SD) [43] approach. SD can be considered as a set of
tools that help in understanding a complex system’s behavior over
time. Since the process of willingness to participate in clinical trials
involves multiple components that interact with each other, it can
be considered a complex system. [44] In this way, a SD model
helps to understand the whole behavior of that system, to predict
their behaviour over time, and to compare different groups (such
as Brazilians and Indians). For example, these kind of analysis are
increasingly used in healthcare research in fields like healthcare
policy to plan cardiovascular disease interventions[45], the spread
of influenca virus [46] and in Neurosciences to investigate
bimanual coordination after strokes.[47]
In our project the SD model had the role of summarizing the
main findings in a causal model and corresponding predicted time
trends that would result under those assumptions. It was not our
intent to provide quantitative predictions. Therefore we have
refrained from adding explicit values on the Y-axis in Figure 2 to
highlight this goal.
The SD model is graphically represented mainly by stocks
(boxes), flows (thick arrows) and variables defining causal loops
(thin arrows). Stocks represents variables that accumulate and
deplete over time, and they are regulated by a flow. In addition,
causal loops were used to create relationships among model
elements through feedback loops which were classified as
‘balancing’ (which promotes the balance of the system) or
‘reinforcing’ loops (which promotes growth of the system). The
+/2 sign at the end of arrows indicate a positive or negative effect,
respectively. After analyzing the results of both meta-analyses, a
preliminary model was created by one of us (GRZ) using the
program Vensim DSS 5.9c for Windows.[48] This is a simulation
software made by Ventana Systems, Inc. (Harvard, Massachusetts
[49]). This baseline model (Figure 2) is composed of two feedback
loops: one reinforcing (represented by the letter ‘R’, which is
promoting growth) and one balancing loop (represented by the
letter ‘B’, which is equilibrating/balancing the system). This kind
of model structure composed by one reinforcing loop sided by one
balancing loop represents a behavior pattern based on the
archetype ‘‘limits to growth’’ or ‘‘limits to success’’ [50].
The resultant baseline model (Figure 2) was then populated with
quantitative values derived from the results of both meta-analyses
(Tables S4 and S5). We then simulated the model to get an
impression of the different behaviors of Brazilian and Indian
eligible people for clinical trials.
The model pathway starts with ‘Patients willing to participate in
clinical trials’, which is the flow that is regulating the amount of
clinical trials of that system. In other words, the more patients
willing to participate, the more clinical trials will be accumulated.
That flow is regulated by the ratio between ‘Motivations to
participate’ (blue arrow, representing positive reinforcement) and
‘Barriers to participate’ (red arrow, representing negative rein-
forcement).
Following the stock of clinical trials, the system proceeds with
the ‘Need to produce more evidence’ which ultimately leads to the
‘Need to recruit more patients to participate in clinical trials’. The
higher the amount of conducted clinical trials in a specific country
is, the more attractive the country will be for further clinical trials
and therefore the ‘‘Need to recruit more patients to participate in
clinical trials’’ will increase. Patient recruitment leads again to
‘Motivations to participate’ and ‘Barriers to participate’ complet-
ing both reinforcing and balancing loops, respectively. The
elements that influence the ‘Motivations to participate’ (conve-
nience, altruism, trust to physicians, monetary reimbursement and
personal health benefits) and ‘Barriers to participate’ (fear of side
effects, inconvenience, language, mistrust, dependency issues, lack
of knowledge and loss of confidentiality) were yielded from the
systematic review and meta-analysis results from Brazilian and
Indian subjects.
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